CS Paper Radar

Large-scale AI-Ready Data for Anti-Cancer Drug Response Modeling

Vincent Lavelle, Yitan Zhu, Kaitlyn Marlor, Thomas Brettin, Rick Stevens

cs.LG q-bio.QM ·submitted 2026-08-11 21:21 UTC · v2
benchmarkdataset

Abstract

Drug response prediction (DRP) models are an active area of research in pharmacogenomics, with growing potential to accelerate the identification of effective anticancer drugs. However, their predictive performance is often constrained by limited dataset scale and insufficient coverages of cancer and chemical spaces. In addition, inconsistent benchmarking practices hinder reliable comparison across models. Standardized frameworks, such as the Innovative Methodologies and New Data for Predictive Oncology Model Evaluation (IMPROVE) project, provide unified data schemas and evaluation protocols for consistent benchmarking, but improving model generalizability requires larger and more diverse training data. In this work, we substantially expand the IMPROVE benchmark through large-scale integration of pharmacogenomic data, primarily from PharmacoDB, together with additional smaller data sources. The expanded resource includes millions of drug response measurements, broader multi-omics coverage, and a major increase in chemical diversity, adding more than 50,000 compounds. To evaluate the impact of the new dataset compared to the original IMPROVE benchmark dataset, we trained DRP models using the two datasets and assess their prediction performance using a common test set and several evaluation strategies, including drug-blind, cancer-blind, and disjoint data splits. While cancer-blind performance remained comparable to the original benchmark, models trained on the expanded dataset showed consistent improvements in drug-blind and disjoint settings, indicating enhanced generalization to previously unseen compounds. These results position the expanded dataset as a community resource that provides a richer foundation for developing DRP models intended to aid in the discovery of novel anticancer drugs.

Closest papers

Nearest neighbours by meaning across the whole index.

PDO Drug Screening Data for Evaluating and Training AI Drug Response Prediction Models

cs.AI q-bio.QM ·2026-11-11 ·Y. Zhu, K. Marlor, V. Lavelle, T. S. Brettin, M. Sacco +4 more
code/data similarity 0.78
Abstract

Anti-cancer drug response prediction (DRP) is critically important for precision oncology and therapeutic development. Currently, most DRP models are developed using drug screening data from immortalized cancer cell lines, which can differ substantially from patient tumors at the genomic and molecular levels, even though patient tumor response is the ultimate prediction target. To help bridge this gap and bring DRP models closer to their intended clinical application, we conducted four drug screening studies using patient-derived organoids (PDOs), which more faithfully recapitulate patient tumors than immortalized cell lines. These studies generated data for improving and evaluating DRP models, including multi-omics profiles of PDO lines, drug feature data, and treatment response measurements. Using these data, we retrained and evaluated multiple publicly available DRP models under three model-building scenarios: training models using cell line data only, training models using combined cell line and PDO data, and pretraining models on cell line data followed by fine-tuning on PDO data. We then evaluated and compared model prediction performance on PDOs across these analysis scenarios. In addition, we also assessed the consistency of drug screening viability data generated by different laboratories using different assay technologies and/or experimental protocols.

0.36

TabBioMed: A Large-Scale Benchmark for Biomedical Tabular Learning

cs.LG ·2026-11-18 ·Pau Mateo-Bernadó, Saivenkata Nagavyjayanthi Polapragada, David Bonet, Pol Arbiol Rakuljic, Laia Mogas Pladevall +6 more
publishedbenchmarkcode/data similarity 0.69
Abstract · 87 pages, 43 figures, including appendices and the NeurIPS paper checklist

Recent advances in machine learning have accelerated biomedical prediction, but evaluation on structured biomedical data remains fragmented, especially for datasets with high dimensionality, large sample size, missingness, and class imbalance. We introduce TabBioMed, a large-scale benchmark of 94 curated public biomedical tabular datasets spanning electronic health records, drug discovery, genomics, transcriptomics, proteomics, metabolomics, single-cell omics, and systems biology. TabBioMed unifies these datasets through a standardized, dataset-aware preprocessing and evaluation framework, enabling reproducible comparison across classification, regression, and multi-target tasks. We benchmark 23 models across classical baselines, gradient-boosted trees, neural tabular architectures, and tabular foundation models. Foundation models deliver the strongest family-level predictive performance. However, their gains are regime-dependent: tree-based models and tuned multilayer perceptrons remain highly competitive, often dominating under inference-time or training-cost constraints. Overall, TabBioMed shows that biomedical tabular learning is strongly context-dependent, with optimal model choice depending on data regime, task type, and computational budget. We release TabBioMed with curated datasets and splits, preprocessing code, baselines, and results, providing a reproducible benchmark for practical model selection and future methods development in biomedical machine learning, available at https://github.com/AI-sandbox/TabBioMed.

0.44

Recent Advances in Deep Learning-Based Drug-Target Binding Affinity Prediction

cs.LG ·2026-08-13 ·Jafin Khan, Md Hossain Shuvo
benchmark similarity 0.69
Abstract

Computational approaches to drug discovery involve multiple sub-problems, and among them, drug-target binding affinity prediction plays an important role. Despite recent advances, accurately predicting binding affinity remains an open research area. The major objective of our paper is to perform a comprehensive review and comparative analysis of recent machine learning methods for drug-target binding affinity prediction, with a focus on identifying strengths, limitations, and research gaps. We review representative recent deep learning approaches that use common benchmark datasets and evaluation metrics, covering a range of neural network architectures and representation strategies. In addition, we analyze seven widely used benchmark datasets and commonly adopted evaluation metrics for drug-target binding affinity prediction. Our analysis indicates that although many methods report strong performance on standard benchmarks, their effectiveness is often influenced by dataset bias and limited evaluation settings. Furthermore, most methods exhibit reduced performance in cold-start scenarios, highlighting challenges in generalization. We identify several limitations of current approaches, including dataset imbalance, the lack of standardized evaluation, limited real-world applicability, and challenges in cold-start scenarios. We also discuss future research directions, including better dataset design, more robust evaluation methods, improved handling of cold-start problems, and the integration of multimodal representations.

0.04

Molecular Prior Networks

cs.LG cs.AIcs.CE ·2026-11-03 ·Pawel Gomoluch, Anthony Bradley
publishedbenchmark similarity 0.68
Abstract · Accepted to the NeurIPS 2026 Workshop on AI for Drug Discovery: Bridging the Translation Gap

Predicting affinity between small molecules and their protein targets remains one of the central problems in drug discovery. Due to the substantial cost of wet-lab experiments, machine learning models of drug-target affinity are usually trained on relatively small datasets, ranging from tens to hundreds of molecules. Given the inherent difficulty of generalization between different targets and chemical series, existing datasets of protein-ligand affinities are typically not used for new projects. At the same time, tabular foundation models, including Prior-data Fitted Networks, have recently shown how transformers can be used to solve machine learning problems in a single forward pass of the network, after being trained over a large corpus of, typically, synthetic datasets. Inspired by that line of work, we propose a novel affinity modelling approach, in which the labels of the query molecules are predicted from the labelled support molecules in a single forward pass of a transformer model. The model is trained on thousands of existing affinity datasets, enabling it to capture the general patterns of molecular activity across different targets, chemical series and dataset sizes. For the smallest support sets, our model matches the state of the art on the regression variant of the FS-Mol benchmark, while being faster than existing methods, thanks to the lack of task-specific training. A comparison against a reduced variant of our architecture, which amounts to kernel regression in a meta-learned feature space, shows that the predictive performance of the transformer model is only partially explained by simple molecular similarity.

0.25

ScreenShot: A Foundation Model for Few-Shot Combination Drug Screening

cs.LG ·2026-08-12 ·Antoine de Mathelin, Christopher Tosh, Wesley Tansey
code/data similarity 0.68
Abstract

Treating patients with combinations of drugs reduces the risk of resistance to any individual drug. Finding effective combinations is difficult because the large search space makes combinatorial screens prohibitively expensive, time consuming, and often technically infeasible. Predictive models can fill this gap, yet existing methods typically require molecular profiling of each sample and per-cohort training, limiting their applicability when time and tissue are scarce. To address this challenge, we introduce ScreenShot, a hierarchical transformer pretrained on 40 drug screening datasets covering 3,700 drugs and 6,000 biological samples, whose architecture mirrors the nested structure of screening data. Given a few-shot context of observations from a new patient, ScreenShot predicts the response of the sample to combination therapies through in-context learning, operating directly on functional measurements with no fine-tuning and no molecular profiling. On four held-out datasets, ScreenShot outperforms all baselines in both prediction accuracy and identification of selectively effective treatments. ScreenShot's internal representations are directly useful for experimental design: we use them to drive a weighted k-means++ active learning strategy that selects which experiments to run, achieving the same hit detection as uniform screening with a third of the budget. Source code and interactive dashboard: https://github.com/tansey-lab/screenshot.

0.24

Few-Shot Bioactivity Prediction with Meta-Learning under Assay Heterogeneity

cs.LG ·2026-10-05 ·Michal Kmicikiewicz, Tommy Rochussen, Vincent Fortuin, Ewa Szczurek
similarity 0.68
Abstract

Accurate bioactivity prediction is a central challenge in early-stage drug discovery, as individual assays often contain too few measurements to train reliable models independently. Meta-learning offers a principled approach to this few-shot setting, but assay heterogeneity may limit its effectiveness. Here, we test this hypothesis and show that meta-learning performance degrades as meta-training tasks become more heterogeneous. To address this, we introduce MetaHeta, a meta-learning framework that accounts for assay heterogeneity by conditioning predictions on auxiliary data from related assays, with relatedness defined flexibly from available assay information. The architecture of MetaHeta combines linear attention over large auxiliary datasets with exact attention over scarce task-specific context, enabling efficient scaling to the former without compromising exact attention over the latter. We demonstrate the benefits of our approach on assays from ChEMBL and BindingDB, improving few-shot bioactivity prediction and downstream compound prioritization in retrospective Bayesian optimization.

0.17

On the Selectivity of Generative Models in Structure-Based Drug Design

cs.LG cs.AI ·2026-10-16 ·Ella Miray Rajaonson, Jungyoon Lee, William Chau, Alan Aspuru-Guzik, Benjamin Sanchez-Lengeling +3 more
top venuebenchmarkcode/data similarity 0.67
Abstract · Accepted as a Presentation at the Neural Information Processing Systems 2026

Designing small-molecule drugs that selectively bind to a target protein while avoiding unintended interactions with other proteins is essential for reducing side effects that contribute substantially to clinical attrition. Although structure-based drug design (SBDD) has advanced rapidly with deep learning, most generative models still optimize binding to a single target and disregard selectivity due to limited training data and unknown off-target interactions. Motivated by this gap, we introduce SELECTBENCH, a comprehensive benchmark assessing the selectivity of generative SBDD models. SELECTBENCH provides three curated evaluation tasks reflecting different real-world drug discovery scenarios: literature-based case studies, safety screening panels used in pharmaceutical development, and large-scale structure-based evaluation sets. We further introduce a suite of metrics to quantify selectivity and conduct a systematic evaluation of nine representative SBDD models, including methods explicitly trained for selectivity and widely-used inference-time guidance techniques. Our results show that even selectivity-trained models achieve only modest off-target discrimination and inference-time guidance provides limited gains, underscoring the need for method improvement. SELECTBENCH provides both a characterization of where current generative SBDD stands on selectivity and an open, extensible platform to accelerate progress. The benchmark is available at https://github.com/lovetaro/selectbench.

0.44

Data-Scarce, Multi-Granular, Multimodal: Benchmark Design for Biosynthetic Gene Clusters

cs.AI ·2026-11-01 ·Hanlin Xiao, Eriko Takano, Mauricio A. Álvarez, Rainer Breitling
top venuebenchmark similarity 0.67
Abstract · 43 pages, including references and appendices. Accepted at NeurIPS 2026 (Evaluations and Datasets Track)

Biosynthetic gene clusters (BGCs) are co-located genes that encode the biosynthesis of specialized metabolites, an important source of antibiotics, anticancer agents, immunosuppressants, and agricultural bioactives. Deep learning, particularly self-supervised foundation models, has spurred interest in BGC sequence modeling, but evaluation has lagged behind: existing benchmarks often rely on coarse classification over small curated datasets, providing limited discrimination among models and insight into downstream utility. We propose a benchmark-design framework in which an informative benchmark should be discriminative, separating models with statistical confidence, and applicable, spanning scientifically meaningful tasks under different levels of generalization. We instantiate this framework as BGC-Bench, which derives five tasks from MIBiG, ranging from A-domain substrate prediction to BGC-molecule retrieval, evaluates them under genotype- and phenotype-shift splits, includes an active-learning setting for label-scarce discovery, and is easily extensible to new tasks and encoders. BGCs further provide a shared testbed across granularities and modalities: BGC-Bench compares twelve encoders on nucleotide, amino-acid, or Pfam-domain sequences, including compositional baselines for each input type, and combines BGC and chemical encoders for cross-modal retrieval. No single representation dominates: the best granularity depends on the biological scale of the task, and pretrained encoders do not consistently outperform other representations across tasks and splits. Active-learning experiments show that most tasks remain data-limited, encoder rankings change with labeling budget, and acquisition strategies yield modest gains. These results show that BGC model evaluation requires task-diverse, shift-aware benchmarks, and the framework can be generalized to benchmark design beyond BGCs.

0.30